GC Genome

GC Genome Current Assets

The Current Assets of GC Genome (340450.KQ) as of Oct 22, 2026 is 2.00 B KRW. In the previous year, Current Assets was 6.72 B KRW — a change of -70.28% (lower).

Current Assets

2.00 BKRW

YoY

-70.28%

Last updated:

Current Assets of GC Genome is 2025 2.00 B KRW. Current Assets of GC Genome was 2024 6.72 B KRW. It decreases by -70.28% lower compared to the previous year.

The GC Genome Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2022
5.75 B KRW
Jan 1, 2023
5.59 B KRW
Jan 1, 2024
6.72 B KRW
Jan 1, 2025
2.00 B KRW
The GC Genome Current Assets history
YEARCurrent AssetsYoY
2.00 BKRW-70.28%
6.72 BKRW+20.27%
5.59 BKRW-2.74%
5.75 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GC Genome Stock analysis

What does GC Genome do? GC Genome Corp provides prenatal and newborn screening genetic testing services, cancer patient precision diagnosis genetic testing services, and precision diagnosis genetic testing for rare diseases. The company also offers health checkup test services. These services are sold to healthcare providers, hospitals, and clinics seeking advanced diagnostic solutions. The firm generates revenue through direct contracts with medical institutions for these specialized genetic testing packages. The company's core products include clinical genome analysis services tailored for specific medical scenarios. Prenatal and newborn screening targets expectant parents and pediatric care facilities, while cancer and rare disease diagnostics serve oncology and specialized medical departments. Health checkup tests are marketed to wellness centers and preventive care programs. GC Genome Corp's business model relies on recurring contracts with healthcare institutions for ongoing genetic testing needs. The firm's services are positioned as premium diagnostic tools for high-value medical applications, attracting clients focused on precision medicine and early disease detection. GC Genome is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GC Genome stock

Current Assets of GC Genome is 2.00 B KRW in 2025.

Current Assets of GC Genome changed from 6.72 B KRW to 2.00 B KRW, representing a -70.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets GC Genome since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's GC Genome historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — GC Genome

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — GC Genome